· Periodic Report
Q3 operating loss of KRW 9.1 billion with no revenue
Immuneoncia had no sales in the third quarter and lost KRW 9.1 billion from its main business, versus a KRW 10.6 billion loss a year earlier.
424870 · KOSDAQ · Based on DART filings
1 total · 20 per page
· Periodic Report
Immuneoncia had no sales in the third quarter and lost KRW 9.1 billion from its main business, versus a KRW 10.6 billion loss a year earlier.
Get app alerts for new disclosures from ImmuneOncia Therapeutics, Inc..